{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:19:52Z","timestamp":1793413192454,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ajo.2022.09.008","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T03:40:21Z","timestamp":1663990821000},"page":"192-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Review of Fibrosis in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"246","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-1107","authenticated-orcid":false,"given":"KAI XIONG","family":"CHEONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHUI MING GEMMY","family":"CHEUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-7081","authenticated-orcid":false,"given":"KELVIN YI CHONG","family":"TEO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajo.2022.09.008_bib0001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2014.10.005","article-title":"Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration","volume":"159","author":"Barikian","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2022.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/archopht.1988.01060140705039","article-title":"Natural course of poorly defined choroidal neovascularization associated with macular degeneration","volume":"106","author":"Bressler","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2022.09.008_bib0003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2415-14-138","article-title":"Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain","volume":"14","author":"Coco","year":"2014","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2022.09.008_bib0004","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/IAE.0b013e318240a516","article-title":"Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings","volume":"32","author":"Cohen","year":"2012","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2022.09.008_bib0005","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00417-009-1081-y","article-title":"Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up","volume":"247","author":"Costagliola","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"13","key":"10.1016\/j.ajo.2022.09.008_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/tvst.10.13.5","article-title":"Three-year outcomes of neovascular age-related macular degeneration in eyes that do not develop macular atrophy or subretinal fibrosis [published correction appears in","volume":"10","author":"Gabrielle","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2022.09.008_bib0007","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","article-title":"Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions","volume":"210","author":"Gillies","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.09.008_bib0008","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12886-017-0544-x","article-title":"Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed ranibizumab","volume":"17","author":"Gonzalez-Buendia","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2022.09.008_bib0009","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0161-6420(93)31466-1","article-title":"Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture","volume":"100","author":"Green","year":"1993","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2022.09.008_bib0010","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000479937","article-title":"Two-year outcomes of a treat-and-extend regimen using intravitreal aflibercept injections for typical age-related macular degeneration","volume":"238","author":"Ito","year":"2017","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.ajo.2022.09.008_bib0011","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2022.09.008_bib0012","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.ophtha.2007.04.030","article-title":"Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Kaiser","year":"2007","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2022.09.008_bib0013","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.oret.2020.02.011","article-title":"Timing of peak vision gains in patients with neovascular age-related macular degeneration treated with ranibizumab","volume":"4","author":"Khurana","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2022.09.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6538192","article-title":"Effects of intravitreal ranibizumab injection on Chinese patients with wet age-related macular degeneration: 5-year follow-up results","volume":"2016","author":"Lu","year":"2016","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.09.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.ajo.2022.09.008_bib0016","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00417-021-05190-4","article-title":"Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration","volume":"260","author":"Roh","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2022.09.008_bib0017","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"issue":"Pt 3","key":"10.1016\/j.ajo.2022.09.008_bib0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/eye.1997.67","article-title":"Seven year follow-up of age-related maculopathy in an elderly British population","volume":"11","author":"Sparrow","year":"1997","journal-title":"Eye (Lond)"},{"issue":"7","key":"10.1016\/j.ajo.2022.09.008_bib0019","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00417-009-1256-6","article-title":"Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years","volume":"248","author":"Spielberg","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2022.09.008_bib0020","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/IAE.0000000000000583","article-title":"anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: Outcomes in eyes with poor initial vision","volume":"35","author":"Toth","year":"2015","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2022.09.008_bib0021","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/eye.2008.349","article-title":"Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration","volume":"23","author":"Unver","year":"2009","journal-title":"Eye (Lond)"},{"issue":"7","key":"10.1016\/j.ajo.2022.09.008_bib0022","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the comparison of age-related macular degeneration treatments trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2022.09.008_bib0023","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2022.09.008_bib0024","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","article-title":"The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration","volume":"3","author":"Cheung","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"10.1016\/j.ajo.2022.09.008_bib0025","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1111\/aos.14905","article-title":"The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world","volume":"100","author":"Llorente-Gonz\u00e1lez","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.09.008_bib0026","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41598-021-03716-8","article-title":"Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration","volume":"12","author":"Roberts","year":"2022","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.ajo.2022.09.008_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.10.14.1","article-title":"Morphologic and microvascular differences between macular neovascularization with and without subretinal fibrosis","volume":"10","author":"Roberts","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"10.1016\/j.ajo.2022.09.008_bib0028","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/IAE.0000000000002779","article-title":"Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration","volume":"40","author":"Teo","year":"2020","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.ajo.2022.09.008_bib0029","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/ceo.13742","article-title":"Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: A single-centre French study","volume":"48","author":"Wolff","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2022.09.008_bib0030","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","volume":"138","author":"Evans","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2022.09.008_bib0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2021.09.033","article-title":"Associations and outcomes of patients with submacular hemorrhage secondary to age-related macular degeneration in the IVAN trial","volume":"236","author":"Mehta","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2022.09.008_bib0032","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/ceo.13367","article-title":"Swept-source optical coherence tomography angiography features of sub-retinal fibrosis in neovascular age-related macular degeneration","volume":"47","author":"Balaskas","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2022.09.008_bib0033","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2018.11.036","article-title":"Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents","volume":"126","author":"Nguyen","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2022.09.008_bib0034","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/IAE.0000000000003267","article-title":"The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration","volume":"42","author":"Chong Teo","year":"2022","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ajo.2022.09.008_bib0035","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.oret.2020.02.012","article-title":"Subretinal fibrosis in HARBOR varies by choroidal neovascularization subtype","volume":"4","author":"Adrean","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"10.1016\/j.ajo.2022.09.008_bib0036","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00441-021-03514-8","article-title":"Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives","volume":"387","author":"Tenbrock","year":"2022","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.ajo.2022.09.008_bib0037","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ajo.2020.11.002","article-title":"Localized optical coherence tomography precursors of macular atrophy and fibrotic scar in the comparison of age-related macular degeneration treatments trials","author":"Finn","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2022.09.008_bib0038","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/aos.14786","article-title":"Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study","volume":"99","author":"Saenz-de-Viteri","year":"2021","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2022.09.008_bib0039","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.oret.2017.08.019","article-title":"Tomographic biomarkers predicting progression to fibrosis in treated neovascular age-related macular degeneration: A multimodal imaging study","volume":"2","author":"Casalino","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"10.1016\/j.ajo.2022.09.008_bib0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1167\/iovs.18-25189","article-title":"Identification and quantification of the angiofibrotic switch in neovascular AMD","volume":"60","author":"Roberts","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2022.09.008_bib0041","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40123-022-00452-8","article-title":"Intravitreal aflibercept therapy and treatment outcomes of eyes with neovascular age-related macular degeneration in a real-life setting: A five-year follow-up investigation","volume":"11","author":"Angermann","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ajo.2022.09.008_bib0042","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211026389","article-title":"The influence of delayed treatment due to COVID-19 on patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"12","author":"Zhao","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.ajo.2022.09.008_bib0043","unstructured":"Higgins JPT, Thomas J, Chandler J, et\u00a0al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Cochrane. n.d. Updated February 2022. Accessed March 1, 2022. www.training.cochrane.org\/handbook"},{"key":"10.1016\/j.ajo.2022.09.008_bib0044","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.ajo.2022.09.008_bib0045","unstructured":"U.S. Department of Health and Human Services. NHLBI Study Quality Assessment Tools. n.d. Updated July 2022. Accessed March 1, 2022. nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"10.1016\/j.ajo.2022.09.008_bib0046","article-title":"Optical coherence tomography angiography features of macular neovascularization in wet age-related macular degeneration: A cross-sectional study","volume":"70","author":"Ahmed","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"issue":"7","key":"10.1016\/j.ajo.2022.09.008_bib0047","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.4103\/ijo.IJO_3156_20","article-title":"Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: A case control study","volume":"69","author":"Alex","year":"2021","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2022.09.008_bib0048","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/IAE.0000000000000746","article-title":"Bridge arch-shaped serous retinal detachment in age-related macular degeneration","volume":"36","author":"Fajnkuchen","year":"2016","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.ajo.2022.09.008_bib0049","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.9.4.13","article-title":"Subretinal fibrosis detection using polarization sensitive optical coherence tomography","volume":"9","author":"Gr\u00e4fe","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2022.09.008_bib0050","article-title":"Morphological features and prognostic significance of multilayered pigment epithelium detachment in age-related macular degeneration [published online ahead of print, 2021 Mar 3]","author":"Kim","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.09.008_bib0051","first-page":"645","article-title":"Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration","volume":"11","author":"K\u00fc\u00e7\u00fck","year":"2018","journal-title":"Int J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2022.09.008_bib0052","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1097\/IAE.0000000000000819","article-title":"Optical coherence tomography angiography features of subretinal fibrosis in age-related macular degeneration","volume":"35","author":"Miere","year":"2015","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.ajo.2022.09.008_bib0053","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1364\/BOE.426650","article-title":"Identification and quantification of fibrotic areas in the human retina using polarization-sensitive OCT","volume":"12","author":"Motschi","year":"2021","journal-title":"Biomed Opt Express"},{"key":"10.1016\/j.ajo.2022.09.008_bib0054","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4263017","article-title":"Treatment of neovascular age-related macular degeneration with anti-VEGF agents: Predictive factors of long-term visual outcomes","volume":"2017","author":"Pedrosa","year":"2017","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.09.008_bib0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/bjophthalmol-2018-313685","article-title":"Anatomical and functional changes in neovascular AMD in remission: Comparison of fibrocellular and fibrovascular phenotypes","volume":"104","author":"Querques","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.09.008_bib0056","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1167\/iovs.15-18694","article-title":"Automated identification and quantification of subretinal fibrosis in neovascular age-related macular degeneration using polarization-sensitive OCT","volume":"57","author":"Roberts","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ajo.2022.09.008_bib0057","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000479437","article-title":"Different clinical courses on long-term follow-up of age-related macular degeneration patients treated with intravitreal anti-vascular endothelial growth factor injections","volume":"238","author":"Sagiv","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ajo.2022.09.008_bib0058","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajo.2020.02.016","article-title":"Spectral-domain optical coherence tomography analysis of fibrotic lesions in neovascular age-related macular degeneration","volume":"214","author":"Souied","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.09.008_bib0059","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000442783","article-title":"Optical coherence tomography angiography of fibrosis in age-related macular degeneration","volume":"56","author":"Souied","year":"2016","journal-title":"Dev Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2022.09.008_bib0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study","volume":"159","author":"Bhisitkul","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2022.09.008_bib0061","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2022.09.008_bib0062","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422003646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422003646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:52:53Z","timestamp":1757598773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422003646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":62,"alternative-id":["S0002939422003646"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.09.008","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Fibrosis in Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}